Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at Jefferies 2019 London Healthcare Conference

LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
November 11, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York

LONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
November 05, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019

Reported positive Phase 2 data with dry powder inhaler formulation Post period end, completed enrollment in Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator LONDON,...
October 29, 2019 03:00 ET | Source: Verona Pharma plc

Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update

LONDON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces...
October 17, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD

LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized...
October 15, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present...
September 19, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019

LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present...
September 09, 2019 09:33 ET | Source: Verona Pharma plc

Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word...
September 03, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
August 09, 2019 04:35 ET | Source: Verona Pharma plc

Verona Pharma plc: PDMR Dealing

LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...